Michel A Cuendet
Overview
Explore the profile of Michel A Cuendet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
1481
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marquez J, Cuendet M, Caino-Lores S, Estrada T, Deelman E, Weinstein H, et al.
J Phys Chem A
. 2025 Feb;
129(9):2317-2324.
PMID: 39903920
The application of molecular dynamics (MD) simulations to study increasingly larger and more complex systems is challenged by the required amounts of trajectory data needed to sample their conformational space...
2.
Andrearczyk V, Schiappacasse L, Raccaud M, Bourhis J, Prior J, Cuendet M, et al.
Neurooncol Adv
. 2025 Feb;
7(1):vdae216.
PMID: 39896076
Background: Effective follow-up of brain metastasis (BM) patients post-treatment is crucial for adapting therapies and detecting new lesions. Current guidelines (Response Assessment in Neuro-Oncology-BM) have limitations, such as patient-level assessments...
3.
Courlet P, Abler D, Guidi M, Girard P, Amato F, Violi N, et al.
CPT Pharmacometrics Syst Pharmacol
. 2023 Jun;
12(8):1170-1181.
PMID: 37328961
The development of immune checkpoint inhibitors (ICIs) has revolutionized cancer therapy but only a fraction of patients benefits from this therapy. Model-informed drug development can be used to assess prognostic...
4.
Abler D, Courlet P, Dietz M, Gatta R, Girard P, Munafo A, et al.
JCO Clin Cancer Inform
. 2023 May;
7:e2200126.
PMID: 37146261
Purpose: A semiautomated pipeline for the collection and curation of free-text and imaging real-world data (RWD) was developed to quantify cancer treatment outcomes in large-scale retrospective real-world studies. The objectives...
5.
Wicky A, Gatta R, Latifyan S, De Micheli R, Gerard C, Pradervand S, et al.
Front Oncol
. 2023 Apr;
13:1043683.
PMID: 37025593
The growing availability of clinical real-world data (RWD) represents a formidable opportunity to complement evidence from randomized clinical trials and observe how oncological treatments perform in real-life conditions. In particular,...
6.
Gautron Moura B, Gerard C, Testart N, Caikovski M, Wicky A, Aedo-Lopez V, et al.
Cancers (Basel)
. 2023 Jan;
15(1).
PMID: 36612030
Combined ipilimumab and nivolumab significantly improve outcomes in metastatic melanoma patients but bear an important financial impact on the healthcare system. Here, we analyze the treatment costs, focusing on irAE....
7.
Cuendet M, Gatta R, Wicky A, Gerard C, Dalla-Vale M, Tavazzi E, et al.
Front Oncol
. 2022 Dec;
12:1043675.
PMID: 36568192
During the acute phase of the COVID-19 pandemic, hospitals faced a challenge to manage patients, especially those with other comorbidities and medical needs, such as cancer patients. Here, we use...
8.
Perez M, Cuendet M, Rohrig U, Michielin O, Zoete V
Methods Mol Biol
. 2022 Mar;
2405:245-282.
PMID: 35298818
The immune system is constantly protecting its host from the invasion of pathogens and the development of cancer cells. The specific CD8 T-cell immune response against virus-infected cells and tumor...
9.
Aedo-Lopez V, Gerard C, Boughdad S, Gautron Moura B, Berthod G, Digklia A, et al.
Cancers (Basel)
. 2022 Mar;
14(5).
PMID: 35267470
To assess the safety and efficacy of ipilimumab plus nivolumab around selective internal radiation therapy (SIRT) in patients with metastatic uveal melanoma (mUM). We present a retrospective, single center study...
10.
Haas L, Elewaut A, Gerard C, Umkehrer C, Leiendecker L, Pedersen M, et al.
Nat Cancer
. 2022 Feb;
2(7):693-708.
PMID: 35121945
How targeted therapies and immunotherapies shape tumors, and thereby influence subsequent therapeutic responses, is poorly understood. In the present study, we show, in melanoma patients and mouse models, that when...